Pacira BioSciences Introduces Inducement Awards for New Hires
Pacira BioSciences, Inc. (Nasdaq: PCRX), based in Brisbane, California, has taken a significant step towards enhancing its workforce by granting inducement awards to seven new employees as part of its ongoing commitment to attract top talent in the field of innovative pain management.
Details of the Inducement Awards
The inducement awards granted on July 2, 2025, are an important element of Pacira’s strategy to foster a strong and dedicated team. Each award is part of the company's Amended and Restated 2014 Inducement Plan, which aims to ensure that new hires have a vested interest in the company's success from day one.
Among the recipients, one individual received stock options covering a total of 3,500 shares of Pacira common stock, while the seven employees were awarded restricted stock units amounting to 12,300 shares. This structured approach not only incentivizes performance but also aligns the interests of the employees with those of the company and its stakeholders.
Structure and Vesting of Awards
The stock options come with a 10-year term and a vesting schedule that spans four years. Notably, 25 percent of the shares will vest on the first anniversary of employment, with equal quarterly installments for the following three years. The exercise price for these options is set at $23.21, which corresponds to the closing trading price of the stock on the day of the grant.
Each restricted stock unit constitutes a contingent right to obtain one share of common stock. The vesting for these units occurs annually in four equal parts starting July 1, 2026. Vesting for both types of awards hinges on the employees maintaining their positions with Pacira, ensuring that the grants reinforce the company’s commitment to long-term employment and stability.
About Pacira and Their Innovative Solutions
Pacira BioSciences is renowned for its groundbreaking work in delivering non-opioid pain therapies that significantly improve patient outcomes. The company markets three key non-opioid treatments:
EXPAREL (bupivacaine liposome injectable suspension)
This product is a long-acting local analgesic designed for infiltration and various nerve block applications, playing a crucial role in postsurgical pain management.
ZILRETTA (triamcinolone acetonide extended-release injectable suspension)
ZILRETTA provides an extended-release formulation specifically indicated for managing osteoarthritis knee pain, offering patients much-needed relief from chronic discomfort.
iovera
This innovative handheld device offers immediate and long-lasting pain relief by delivering controlled doses of cold temperature to targeted nerves, marking a significant advancement in non-drug pain management.
Additionally, Pacira is actively advancing its gene therapy, PCRX-201 (enekinragene inzadenovec), which is poised to tackle prevalent conditions such as osteoarthritis. The company's cutting-edge therapies showcase its dedication to improving patient lives through safer, effective alternatives.
Conclusion
By reinforcing its team with inducement grants, Pacira BioSciences not only attracts exceptional talent but also strengthens its commitment to innovation in pain management. As more challenges surface in the field of healthcare, the role of such forward-thinking companies becomes increasingly vital.
Frequently Asked Questions
What is the purpose of the inducement grants at Pacira?
The inducement grants aim to attract and retain talented employees by aligning their interests with those of the company through equity awards.
Who approved the inducement awards at Pacira?
The People & Compensation Committee of the Board of Directors approved the inducement awards, following Nasdaq Listing Rule 5635(c)(4).
What are the main products offered by Pacira?
Pacira offers innovative non-opioid treatments including EXPAREL, ZILRETTA, and iovera, aimed at various pain management needs.
How does the vesting of stock options work?
The stock options vest over four years, where 25% vests after one year, followed by equal quarterly installments over the next three years.
What is PCRX-201 and its significance?
PCRX-201 is a novel gene therapy being developed by Pacira that could potentially address widespread conditions like osteoarthritis, representing a significant innovation in treatment options.
